Soichiro Nakako, Hiroshi Shiragami, Mitsuharu Hashimura, Hiroyoshi Ichihara, Atsuko Mugitani
[Rinsho ketsueki] The Japanese journal of clinical hematology 2021A 67-year-old man with multiple myeloma had been treated with carfilzomib, lenalidomide, and dexamethasone (KRd) therapy. During the second course, he developed dyspnea, which gradually worsened. After admission, gastrointestinal losses of magnesium were confirmed, and intravenous magnesium was administered, which consequently improved his symptoms. Although KRd therapy was resumed, hypomagnesemia was recurring. Therefore, carfilzomib was replaced with ixazomib, which improved the patient's hypomagnesemia. The major causes of hypomagnesemia are gastrointestinal and renal losses; our case appeared to have gastrointestinal losses of magnesium and was successfully treated by discontinuing carfilzomib. Hypomagnesemia should be considered in patients receiving carfilzomib; furthermore, clinicians should consider discontinuing carfilzomib as its treatment.
Soichiro Nakako, Hiroshi Shiragami, Mitsuharu Hashimura, Hiroyoshi Ichihara, Atsuko Mugitani. Hypomagnesemia induced by gastrointestinal losses due to carfilzomib]. [Rinsho ketsueki] The Japanese journal of clinical hematology. 2021;62(3):190-192
PMID: 33828013
View Full Text